Akorn, Inc. Announces Positive Phase III Pivotal Trial Results for Akten(R)
23 1์ 2007 - 9:00PM
Business Wire
Akorn, Inc. (AMEX: AKN) today announced the positive results of a
Phase III pivotal trial for Akten๏ฟฝ. The clinical trial was a
randomized, placebo controlled, multi-centered, 4-arm trial in 209
subjects. The primary efficacy end point for achieving ocular
anesthesia (p
Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AMEX:AKN)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 9์(9) 2024 ์ผ๋ก 10์(10) 2024
Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AMEX:AKN)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 10์(10) 2023 ์ผ๋ก 10์(10) 2024
Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (์๋ฉ๋ฆฌ์นด ์ฆ๊ถ๊ฑฐ๋์)์ ์ค์๊ฐ ๋ด์ค: ์ต๊ทผ ๊ธฐ์ฌ 0
More Akorn, Inc. News Articles